Arcus Biosciences is a high-risk speculation with major upcoming catalysts, despite stock declines and Gilead's exit from the ...

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

Utilities sector outperformed the S&P 500 in Q1 2025 with a 3.38% gain. Learn about top-performing stocks, earnings growth, and ETF insights.

Arcutis Biotherapeutics (NASDAQ:ARQT) stock climbs as a patent lawsuit with Padagis over its lead product Zoryve pauses. Read ...

BrainsWay's Q4 performance was strong, but a rising share count and flat margins have kept the stock from moving higher.

Timken downgraded at Jefferies, saying potential for lower volumes and margin compression due to weakening short-cycle ...

Executive Briefing at OFC 2025 Conference Call April 2, 2025 11:30 AM ETCompany ParticipantsFederico Guillen - President, ...

Hermès was one of the few luxury stocks rated Buy last November due to its robust fundamentals and favourable market ...